Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Up 58.7% in October

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) saw a significant growth in short interest in October. As of October 31st, there was short interest totalling 160,100 shares, a growth of 58.7% from the October 15th total of 100,900 shares. Based on an average trading volume of 117,900 shares, the short-interest ratio is presently 1.4 days.

Enlivex Therapeutics Trading Down 8.5 %

Shares of ENLV stock traded down $0.10 on Thursday, reaching $1.08. The company’s stock had a trading volume of 158,627 shares, compared to its average volume of 117,266. The stock’s fifty day simple moving average is $1.45 and its 200-day simple moving average is $1.40. Enlivex Therapeutics has a 1 year low of $1.08 and a 1 year high of $4.59. The company has a market capitalization of $23.12 million, a price-to-earnings ratio of -0.92 and a beta of 1.11.

Enlivex Therapeutics (NASDAQ:ENLV) last released its earnings results on Friday, August 30th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.06. Equities research analysts forecast that Enlivex Therapeutics will post -0.7 earnings per share for the current year.

Institutional Investors Weigh In On Enlivex Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Armistice Capital LLC acquired a new position in Enlivex Therapeutics in the second quarter valued at approximately $2,415,000. Sigma Investment Counselors Inc. acquired a new position in Enlivex Therapeutics in the third quarter valued at approximately $50,000. Finally, XTX Topco Ltd acquired a new position in shares of Enlivex Therapeutics during the 2nd quarter worth approximately $35,000. Institutional investors and hedge funds own 1.02% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on ENLV shares. EF Hutton Acquisition Co. I raised shares of Enlivex Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 27th. HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Enlivex Therapeutics in a report on Friday, September 27th.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.